AVENIO ctDNA Targeted Kit V2

Material Number: Select a variation

Next-generation sequencing (NGS) liquid biopsy tumor profiling assay for identifying genomic aberrations in solid tumors containing 17 genes.

The AVENIO ctDNA Targeted Kit V2 is a next-generation sequencing (NGS) liquid biopsy research assay that contains 17 genes, including those in U.S. National Comprehensive Cancer Network (NCCN) Guidelines.1 The Targeted panel may be used for pan-cancer research applications, but is specially optimized for lung cancer and colorectal cancer (CRC) research. The AVENIO ctDNA Targeted Kit V2 is an efficient tumor profiling solution.

Features and Benefits

  • Includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1
  • All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
  • Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
  • Includes reagents, bioinformatics and software
  • Streamlined, end-to-end research workflow from extraction to analysis and reporting in five days


  • Panel size: 81 kb
  • Sample size: 4 ml of plasma
  • ctDNA input: 10-50 ng
  • Reactions per kit: 16
  • Turn-around time: 5 days from extraction to results


Box # Sub-kit name
1 AVENIO cfDNA Isolation Kit V2
2 AVENIO Library Prep Kit V2
3 AVENIO cfDNA Enrichment Kit V2
4 AVENIO ctDNA Targeted Panel V2
5 AVENIO Post-Hybridization Kit V2

Exceptional Performance3

View the full gene list


  1. National Comprehensive Cancer Network. Accessed August 2, 2023
  2. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 2014;20(5):548–554 doi:10.1038/nm.3519
  3. Data on file with Roche.

Product variations

Material Number Name Price
09733736001 AVENIO ctDNA Targeted Kit V2 - 16 rxn Log in or register to see the price

Other products in this category